1. Academic Validation
  2. Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology

  • Bioorg Med Chem Lett. 2018 Jun 15;28(11):2029-2034. doi: 10.1016/j.bmcl.2018.04.063.
Sobhana Babu Boga 1 Abdul-Basit Alhassan 2 Alan B Cooper 2 Ronald Doll 2 Neng-Yang Shih 2 Gerald Shipps 3 Yongqi Deng 3 Hugh Zhu 2 Yang Nan 3 Robert Sun 2 Liang Zhu 3 Jagdish Desai 2 Mehul Patel 3 Kiran Muppalla 3 Xiaolei Gao 2 James Wang 2 Xin Yao 2 Joseph Kelly 2 Subrahmanyam Gudipati 2 Sunil Paliwal 2 Hon-Chung Tsui 2 Tong Wang 3 Bradley Sherborne 2 Li Xiao 2 Alan Hruza 2 Alexei Buevich 2 Li-Kang Zhang 2 David Hesk 2 Ahmed A Samatar 2 Donna Carr 2 Brian Long 2 Stuart Black 2 Priya Dayananth 2 William Windsor 2 Paul Kirschmeier 2 Robert Bishop 2
Affiliations

Affiliations

  • 1 Discovery Chemistry, Merck & Co., Inc., 2015 Galloping Hill Rd, Kenilworth, NJ 07033, United States. Electronic address: sobhana.babu.boga@merck.com.
  • 2 Discovery Chemistry, Merck & Co., Inc., 2015 Galloping Hill Rd, Kenilworth, NJ 07033, United States.
  • 3 Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, United States.
Abstract

Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 μM h; F% = 0) which precluded further development. In an effort to identify novel ERK inhibitors with improved PK properties with respect to 5, a systematic exploration of sterics and composition at the 3-position of the pyrrolidine led to the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 28 with vastly improved PK (rat AUC PK @10 mpk = 26 μM h; F% = 70).

Keywords

ATP competitive; ERK inhibitor; Kinase selectivity; MAP kinases; Oncology.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-112300
    ERK Inhibitor
    ERK